November 20th 2024
Under the collaboration, the companies will create and test circVec DNA–LNP formulations with an eye toward potential therapeutic applications.
October 30th 2024
The collaboration aims to develop precision genetic medicines using ViaNautis’ proprietary polyNaut technology platform.
September 10th 2024
Alternative delivery methods for biologics continues to be explored that offer less invasive, less painful administration.
August 8th 2024
AAV and lentivirus both have pros and cons in their use for specific gene therapy applications.
July 3rd 2024
The company is referring to its search for innovative approaches as crowdsourcing and will award at least one cash prize.